#B-select Monoclonal Antibodies # Curious in learning new things #Anatomy
2018 conference #November 14-15, 2018@San Antonio, USA #To know more.. https://bit.ly/2Jbx4nq
Aduro’s B-select platform
employs a proprietary ultra-selective functional screening process to identify
antibodies with unique binding properties against a broad repertoire of targets
that can modulate key targets in immuno-oncology.
The technology is based
on in vitro clonal expansion of B cells (antibody-producing cells) isolated
from the spleen or lymph nodes of immunized animals, capable of rescuing one of
every two antigen-specific B cells induced in mice. This unprecedented
efficiency enables exploration of the full repertoire of B cells induced to
uncover unique antibodies with pre-specified function (the ‘needles in the
haystack’) in validated and proprietary targets.
Using this platform,
Aduro has developed a deep pipeline of both preclinical and clinical monoclonal
antibodies (B-select mAbs) that have the potential to regulate the immune
system of patients with cancer. Aduro’s pipeline includes antagonists and a
checkpoint inhibitor, which is intended
to activate the immune system by removing suppression – this is also known as
“releasing the brakes” on the immune system. In addition, Aduro has developed
agonists, which are unique antibodies that stimulate immune responses when
cancer is not detected by the immune system. These mAbs are designed to be used
alone or in combination with other therapies, including the STING and LADD® platforms
to increase immunotherapy potency and durability.
Aduro is currently
evaluating BION-1301, its most advanced proprietary B-select mAb, as a novel
therapy for multiple myeloma. Despite new treatments recently approved in
multiple myeloma, this disease remains incurable as patients relapse, or become
resistant to, currently-available therapies. Aduro has established that A
PRoliferation-Inducing Ligand (APRIL) plays a crucial part in the protective
bone marrow tumor microenvironment. In preclinical studies, APRIL, through the
B cell maturation antigen (BCMA), was shown to be critically involved in the
survival, proliferation and chemoresistance of multiple myeloma, and
upregulates mechanisms of immunoresistance, including PD-L1 upregulation.
BION-1301, a humanized antibody that blocks APRIL from binding to its
receptors, has been shown in preclinical studies to halt tumor growth and
overcome drug resistance. BION-1301 is currently being evaluated in a Phase 1/2
clinical study.
Aduro’s second lead
candidate is an anti-CD27 antibody being advanced by Merck under its
collaboration agreement. CD27 has been recognized as having a critical role in
activating a productive anti-cancer (CD8 T-cell) immune response and has
demonstrated the potential to be combined with checkpoint inhibitors in
pre-clinical studies. Aduro’s anti-CD27 antibody is distinct because it targets
a functional epitope on CD27 which demonstrated potent activation of the CD27
co-stimulatory pathway in pre-clinical studies.
No comments:
Post a Comment